SAFETY DATA SHEET

Losartan / Hydrochlorothiazide Formulation

Version 4.2  Revision Date: 09/13/2019  SDS Number: 17068-00014  Date of last issue: 24.04.2019
Date of first issue: 30.09.2014

1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Losartan / Hydrochlorothiazide Formulation

Manufacturer or supplier’s details
Company: MSD
Address: Briahnager - Off Pune Nagar Road
Wagholi - Pune - India 412 207
Telephone: 908-740-4000
Emergency telephone number: 1-908-423-6000
E-mail address: EHSDATASTEWARD@msd.com
Telefax: 908-735-1496

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification
Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification
Acute toxicity (Oral): Category 5
Serious eye damage/eye irritation: Category 1
Skin sensitisation: Category 1
Reproductive toxicity: Category 1B
Effects on or via lactation
Specific target organ toxicity - repeated exposure: Category 2 (Kidney, Parathyroid gland)
Specific target organ toxicity - repeated exposure (Oral): Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

GHS label elements
Hazard pictograms: ![Hazard Pictograms]

Signal word: Danger

Hazard statements:
- H303 May be harmful if swallowed.
- H317 May cause an allergic skin reaction.
- H318 Causes serious eye damage.
- H360D May damage the unborn child.
- H362 May cause harm to breast-fed children.
- H373 May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.
- H373 May cause damage to organs (Blood, Cardiovascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P202 Do not handle until all safety precautions have been read and understood.
- P260 Do not breathe dust.
- P263 Avoid contact during pregnancy and while nursing.
- P264 Wash skin thoroughly after handling.
- P270 Do not eat, drink or smoke when using this product.
- P272 Contaminated work clothing should not be allowed out of the workplace.
- P280 Wear protective gloves/protective clothing/eye protection/face protection.

**Response:**
- P301 + P312 IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell.
- P302 + P352 IF ON SKIN: Wash with plenty of water.
- P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
- P308 + P313 IF exposed or concerned: Get medical advice/attention.
- P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.
- P362 + P364 Take off contaminated clothing and wash it before reuse.

**Storage:**
- P405 Store locked up.

**Disposal:**
- P501 Dispose of contents/container to an approved waste disposal plant.

Other hazards which do not result in classification:
Contact with dust can cause mechanical irritation or drying of the skin.
SAFETY DATA SHEET
Losartan / Hydrochlorothiazide Formulation

Version 4.2  Revision Date: 09/13/2019  SDS Number: 17068-00014  Date of last issue: 24.04.2019
Date of first issue: 30.09.2014

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Losartan</td>
<td>124750-99-8</td>
<td>&gt;= 20 - &lt; 30</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>&gt;= 10 - &lt; 20</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>58-93-5</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May be harmful if swallowed.
May cause an allergic skin reaction.
Causes serious eye damage.
May damage the unborn child.
May cause harm to breast-fed children.
May cause damage to organs through prolonged or repeated exposure.
Contact with dust can cause mechanical irritation or drying of the skin.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
SAFETY DATA SHEET

Losartan / Hydrochlorothiazide Formulation

Unsuitable extinguishing media: Dry chemical

Specific hazards during firefighting:
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
- Carbon oxides
- Chlorine compounds
- Nitrogen oxides (NOx)
- Chlorine compounds
- Sulphur oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for firefighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Losartan</td>
<td>124750-99-8</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>58-93-5</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type
Hand protection Material: Chemical-resistant gloves
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions,
mists or aerosols, wear the appropriate goggles. Wear a face shield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder

Colour: yellow

Odour: odourless

Odour Threshold: No data available

pH: No data available

Melting point/freezing point: No data available

Initial boiling point and boiling range: No data available

Flash point: Not applicable

Evaporation rate: Not applicable

Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids): No data available

Upper explosion limit / Upper flammability limit: No data available

Lower explosion limit / Lower flammability limit: No data available

Vapour pressure: Not applicable

Relative vapour density: Not applicable

Relative density: No data available

Density: No data available
10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks. Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
        Skin contact
        Ingestion
        Eye contact

Acute toxicity
May be harmful if swallowed.

Product:
Acute oral toxicity : Acute toxicity estimate: 2,273 mg/kg
Method: Calculation method

Components:
Cellulose:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
        Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

**Losartan:**
- Acute oral toxicity: LD50 (Mouse): 1,257 - 1,590 mg/kg
- LDLo (Rat): 200 mg/kg
- LDLo (Mouse): 400 mg/kg

**Starch:**
- Acute oral toxicity: LD50 (Mouse): > 5,000 mg/kg

**Hydrochlorothiazide:**
- Acute oral toxicity: LD50 (Rat): 10,000 mg/kg
- LD50 (Mouse): 10,000 mg/kg
- Acute toxicity (other routes of administration): LD50 (Rat): 990 mg/kg
  Application Route: Intravenous
- LD50 (Dog): 250 mg/kg
  Application Route: Intravenous

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Losartan:**
- Species: Rabbit
- Result: Mild skin irritation

**Hydrochlorothiazide:**
- Species: Rabbit
- Result: No skin irritation

**Serious eye damage/eye irritation**
Causes serious eye damage.

**Components:**

**Losartan:**
- Species: Rabbit
- Result: Severe irritation

**Hydrochlorothiazide:**
- Species: Rabbit
- Result: Mild eye irritation
Respiratory or skin sensitisation

Skin sensitisation
May cause an allergic skin reaction.

Respiratory sensitisation
Not classified based on available information.

Components:

Losartan:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Assessment: Probability or evidence of skin sensitisation in humans
Result: positive

Germ cell mutagenicity
Not classified based on available information.

Components:

Cellulose:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Losartan:
Genotoxicity in vitro: Test Type: in vitro assay
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Test Type: Chromosomal aberration
Result: negative

Genotoxicity in vivo: Test Type: Chromosomal aberration
Result: negative

Hydrochlorothiazide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: Chinese hamster ovary cells
Result: positive

Test Type: in vitro assay
Test system: mouse lymphoma cells
Result: positive

Genotoxicity in vivo:

Test Type: Chromosomal aberration
Species: Chinese hamster
Cell type: Bone marrow
Result: negative

Test Type: in vivo assay
Species: Mouse
Cell type: Bone marrow
Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.

Components:

Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Losartan:
Species: Mouse
Application Route: Oral
Exposure time: 92 weeks
Dose: 200 mg/kg body weight
Result: negative

Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Dose: 270 mg/kg body weight
Result: negative

Hydrochlorothiazide:
Species: Mouse, female
<table>
<thead>
<tr>
<th>Application Route</th>
<th>Oral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure time</td>
<td>2 Years</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
</tbody>
</table>

Species: Mouse, male
Application Route: Oral
Exposure time: 2 Years
Result: equivocal

Species: Rat, male and female
Application Route: Oral
Exposure time: 2 Years
Result: negative

**Reproductive toxicity**
May damage the unborn child.
May cause harm to breast-fed children.

**Components:**

**Cellulose:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: One-generation reproduction toxicity study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Result:</td>
<td>negative</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Fertility/early embryonic development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Result:</td>
<td>negative</td>
</tr>
</tbody>
</table>

**Losartan:**

<table>
<thead>
<tr>
<th>Effects on fertility</th>
<th>Test Type: Fertility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat, female</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Oral</td>
</tr>
<tr>
<td>Fertility: LOAEL:</td>
<td>200 mg/kg body weight</td>
</tr>
<tr>
<td>Result:</td>
<td>female reproductive effects</td>
</tr>
<tr>
<td>Remarks:</td>
<td>Maternal toxicity observed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effects on foetal development</th>
<th>Test Type: Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rabbit</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Oral</td>
</tr>
<tr>
<td>General Toxicity Maternal:</td>
<td>NOAEL: 10 mg/kg body weight</td>
</tr>
<tr>
<td>Developmental Toxicity:</td>
<td>NOAEL F1: 20 mg/kg body weight</td>
</tr>
<tr>
<td>Result:</td>
<td>Embryotoxic effects and adverse effects on the off-</td>
</tr>
<tr>
<td></td>
<td>spring were detected only at high maternally toxici</td>
</tr>
<tr>
<td></td>
<td>effects, No teratogenic effects</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Type:</th>
<th>Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species:</td>
<td>Rat</td>
</tr>
<tr>
<td>Application Route:</td>
<td>Oral</td>
</tr>
<tr>
<td>Developmental Toxicity:</td>
<td>LOAEL: 10 mg/kg body weight</td>
</tr>
<tr>
<td>Result:</td>
<td>Fetotoxicity, No teratogenic effects</td>
</tr>
</tbody>
</table>
Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments. Studies indicating a hazard to babies during the lactation period.

**Hydrochlorothiazide:**

*Effects on fertility:*

- **Test Type:** Fertility
- **Species:** Rat, male and female
- **Application Route:** oral (feed)
- **Fertility:** NOAEL: 4 mg/kg body weight
- **Result:** Effects on fertility

- **Test Type:** Fertility
- **Species:** Mouse, male and female
- **Application Route:** oral (feed)
- **Fertility:** NOAEL: 100 mg/kg body weight
- **Result:** Effects on fertility

*Effects on foetal development:*

- **Test Type:** Development
- **Species:** Mouse
- **Application Route:** Oral
- **Developmental Toxicity:** NOAEL: 3,000 mg/kg body weight
- **Result:** No teratogenic effects

- **Test Type:** Development
- **Species:** Rat
- **Application Route:** Oral
- **Developmental Toxicity:** NOAEL: 1,000 mg/kg body weight
- **Result:** No teratogenic effects

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

**Components:**

**Losartan:**

- **Exposure routes:** Ingestion
- **Target Organs:** Blood, Cardio-vascular system, Stomach, Kidney
- **Assessment:** May cause damage to organs through prolonged or repeated exposure.

**Hydrochlorothiazide:**

- **Target Organs:** Kidney, Parathyroid gland
- **Assessment:** Causes damage to organs through prolonged or repeated exposure.
Repeated dose toxicity

**Components:**

**Cellulose:**
- **Species:** Rat
- **NOAEL:** >9,000 mg/kg
- **Application Route:** Ingestion
- **Exposure time:** 90 Days

**Losartan:**
- **Species:** Rat
- **LOAEL:** 15 mg/kg
- **Application Route:** Oral
- **Exposure time:** 309 d
- **Number of exposures:** daily
- **Target Organs:** Blood, Kidney, Cardio-vascular system, Stomach

- **Species:** Dog
- **NOAEL:** 5 mg/kg
- **Application Route:** Oral
- **Exposure time:** 1 Months
- **Symptoms:** Salivation, Vomiting

- **Species:** Dog
- **LOAEL:** 25 mg/kg
- **Application Route:** Oral
- **Exposure time:** 53 Weeks
- **Number of exposures:** daily
- **Symptoms:** Salivation, Vomiting

**Hydrochlorothiazide:**
- **Species:** Rat, male and female
- **LOAEL:** 10 mg/kg
- **Application Route:** Oral
- **Exposure time:** 2 yr
- **Target Organs:** Kidney, Parathyroid gland

- **Species:** Mouse, male and female
- **NOAEL:** 300 - 550 mg/kg
- **Application Route:** Oral
- **Exposure time:** 2 yr
- **Remarks:** No significant adverse effects were reported

- **Species:** Dog
- **Application Route:** Oral
- **Exposure time:** 9 Months
- **Target Organs:** Parathyroid gland

Aspiration toxicity

Not classified based on available information.
Components:

Losartan:
No aspiration toxicity classification

Hydrochlorothiazide:
No aspiration toxicity classification

Experience with human exposure

Components:

Losartan:
- Eye contact: Symptoms: Eye irritation
- Ingestion: Symptoms: hypotension, tachycardia

Hydrochlorothiazide:
- Eye contact: Symptoms: Eye irritation
- Ingestion: Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:
- Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
  Exposure time: 48 h
  Remarks: Based on data from similar materials

Losartan:
- Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 929 mg/l
  Exposure time: 96 h
  Method: FDA 4.11

- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 331 mg/l
  Exposure time: 48 h
  Method: OECD Test Guideline 202

- Toxicity to algae/aquatic plants: NOEC (Microcystis aeruginosa (blue-green algae)): 949 mg/l
  Exposure time: 10 d
  Method: FDA 4.01

  NOEC (Selenastrum capricornutum (green algae)): 143 mg/l
  Exposure time: 10 d
  Method: FDA 4.01

- Toxicity to fish (Chronic toxicity): NOEC: 10 mg/l
  Exposure time: 32 d
  Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC: 100 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Hydrochlorothiazide:
Toxicity to fish:
LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): > 500 mg/l
Exposure time: 48 h

Persistence and degradability

Components:

Cellulose:
Biodegradability: Result: Readily biodegradable.

Losartan:
Stability in water: Hydrolysis: < 10 % (5 d)

Hydrochlorothiazide:
Stability in water: Hydrolysis: 46.2 % (96 h)

Bioaccumulative potential

Components:

Losartan:
Partition coefficient: n-octanol/water: log Pow: 1.2

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.
14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to IMO instruments
Not applicable for product as supplied.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information

Date format : dd.mm/yyyy

Full text of other abbreviations
ACGIH : USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA : 8-hour, time-weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.